Inflammation and immune responses in atherosclerosis

Trends in Immunology

Volumn 23, Issue 11, 2002, Pages 535-541

  Greaves, David R ^a   Channon, Keith M ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR ANTIBODY; GAMMA INTERFERON; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 8; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LIPOXYGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PRAVASTATIN; RECEPTOR ANTIBODY; STATIN; THIAZOLIDINE DERIVATIVE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CELL MOVEMENT; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; MODELS, IMMUNOLOGICAL;

EID: 0036839228     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02331-1     Document Type: Review

References (53)

1. Zimmet P., et al. Global and societal implications of the diabetes epidemic. Nature. 414:2001;782-787.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 104:2001;365-372.
3. Cybulsky M.I., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107:2001;1255-1262.
4. Dansky H.M., et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler. Thromb. Vasc. Biol. 21:2001;1662-1667.
5. Suzuki H., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386:1997;292-296.
6. Febbraio M., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105:2000;1049-1056.
7. Janeway C.A. Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20:2002;197-216.
8. Xu X.H., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 104:2001;3103-3108.
9. Edfeldt K., et al. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 105:2002;1158-1161.
10. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:2001;1876-1890.
11. Dansky H.M., et al. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U. S. A. 94:1997;4642-4646.
12. Paulsson G., et al. Oligoclonal T-cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20:2000;10-17.
13. Caligiuri G., et al. Evidence for antigen-driven T-cell response in unstable angina. Circulation. 102:2000;1114-1119.
14. Streblow D.N., et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle-cell migration. Cell. 99:1999;511-520.
15. Muhlestein J.B., et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:1998;633-636.
16. Blessing E., et al. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis. 158:2001;13-17.
17. Caligiuri G., et al. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation. 103:2001;2834-2838.
18. Danesh J., et al. Chronic infections and coronary heart disease: is there a link? Lancet. 350:1997;430-436.
19. Danesh J., et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur. Heart J. 23:2002;371-375.
20. Parchure N., et al. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation. 105:2002;1298-1303.
21. Palinski W., Witztum J.L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J. Intern. Med. 247:2000;371-380.
22. Wick G., et al. Atherosclerosis as an autoimmune disease: an update. Trends Immunol. 22:2001;665-669.
23. Glass C.K., Witztum J.L. Atherosclerosis. The road ahead. Cell. 104:2001;503-516.
24. Gupta S., et al. IFN-γ potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99:1997;2752-2761.
25. Gerdes N., et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells and macrophages: implications for atherogenesis. J. Exp. Med. 195:2002;245-257.
26. Whitman S.C., et al. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-γ Circ. Res. 90:2002;E34-E38.
27. Mallat Z., et al. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85:1999;e17-24.
28. -/- mice. FASEB J. 15:2001;2730-2732.
29. Proudfoot A.E. Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. Immunol. 2:2002;106-115.
30. Gu L., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2:1998;275-281.
31. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:1998;894-897.
32. Rollins B.J. Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease. J. Clin. Invest. 108:2001;1269-1271.
33. Greaves D.R., et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 21:2001;923-929.
34. Haley K.J., et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation. 102:2000;2185-2189.
35. Mach F., et al. Differential expression of three T-lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 104:1999;1041-1050.
36. McDermott D.H., et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ. Res. 89:2001;401-407.
37. Moatti D., et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 97:2001;1925-1928.
38. Aiello R.J., et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol. 22:2002;443-449.
39. Cyrus T., et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest. 103:1999;1597-1604.
40. Cyrus T., et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation. 103:2001;2277-2282.
41. Schonbeck U., Libby P. CD40 signaling and plaque instability. Circ. Res. 89:2001;1092-1103.
42. Libby P., et al. Inflammation and atherosclerosis. Circulation. 105:2002;1135-1143.
43. de Beer F.C., et al. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J. Exp. Med. 156:1982;230-242.
44. Bhakdi S., et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol. 19:1999;2348-2354.
45. Buono C., et al. Influence of C3 deficiency on atherosclerosis. Circulation. 105:2002;3025-3031.
46. Kwak B.R., Mach F. Statins inhibit leukocyte recruitment: new evidence for their anti-inflammatory properties. Arterioscler. Thromb. Vasc. Biol. 21:2001;1256-1258.
47. Diomede L., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler. Thromb. Vasc. Biol. 21:2001;1327-1332.
48. Albert M.A., et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 286:2001;64-70.
49. Cockerill G.W., et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 103:2001;108-112.
50. Van Lenten B.J., et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 103:2001;2283-2288.
51. Ricote M., et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
52. Chen Z., et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 21:2001;372-377.
53. Li A.C., et al. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106:2000;523-531.